Literature DB >> 33510177

Lung cancer patients' comorbidities and attendance of German ambulatory physicians in a 5-year cross-sectional study.

Jasmin Bossert1, Marion Ludwig2, Pamela Wronski3, Jan Koetsenruijter3, Katja Krug3, Matthias Villalobos4, Josephine Jacob2, Jochen Walker2, Michael Thomas4, Michel Wensing3.   

Abstract

The majority of lung cancer patients are diagnosed with an advanced stage IV, which has short survival time. Many lung cancer patients have comorbidities, which influence treatment and patients' quality of life. The aim of the study is to describe comorbidities in incident lung cancer patients and explore their attendance of ambulatory care physicians in Germany. In the observed period, 13,111 persons were first diagnosed with lung cancer (1-year incidence of 36.4 per 100,000). The mean number of comorbidities over 4 quarters was 30.77 ± 13.18; mean Charlson Comorbidity Index was 6.66 ± 2.24. In Germany, ambulatory care physicians most attended were general practitioners (2.6 quarters with contact within 4 quarters). Lung cancer was diagnosed by a general practitioner in 38% of the 13,111 incident patients. The average number of ambulatory care physician contacts over 4 quarters was 35.82 ± 27.31. High numbers of comorbidities and contacts in ambulatory care are common in patients with lung cancer. Therefore, a cross-sectoral and interdisciplinary approach is required for effective, patient-centred care. This was a 5-year cross-sectoral study, based on the InGef research database, which covers anonymized health insurance data of 7.2 million individuals in Germany. Incident lung cancer patients in a 5-year period (2013-2017) were identified. Descriptive statistics were calculated for sociodemographic characteristics, comorbidities, and attendance of ambulatory care physicians.

Entities:  

Year:  2021        PMID: 33510177      PMCID: PMC7844218          DOI: 10.1038/s41533-020-00214-8

Source DB:  PubMed          Journal:  NPJ Prim Care Respir Med        ISSN: 2055-1010            Impact factor:   2.871


  27 in total

1.  Cross-sectoral cancer care: views from patients and health care professionals regarding a personal electronic health record.

Authors:  I Baudendistel; E C Winkler; M Kamradt; S Brophy; G Längst; F Eckrich; O Heinze; B Bergh; J Szecsenyi; D Ose
Journal:  Eur J Cancer Care (Engl)       Date:  2016-02-03       Impact factor: 2.520

2.  [Health monitoring at the Robert Koch Institute. Status and perspectives].

Authors:  B-M Kurth; C Lange; P Kamtsiuris; H Hölling
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2009-05       Impact factor: 1.513

Review 3.  Comorbidities in lung cancer.

Authors:  Agata Ewa Dutkowska; Adam Antczak
Journal:  Pneumonol Alergol Pol       Date:  2016

Review 4.  The impact of comorbidity on cancer and its treatment.

Authors:  Diana Sarfati; Bogda Koczwara; Christopher Jackson
Journal:  CA Cancer J Clin       Date:  2016-02-17       Impact factor: 508.702

5.  The impact of comorbidity upon determinants of outcome in patients with lung cancer.

Authors:  Derek Grose; David S Morrison; Graham Devereux; Richard Jones; Dave Sharma; Colin Selby; Kirsty Docherty; David McIntosh; Marianne Nicolson; Donald C McMillan; Robert Milroy
Journal:  Lung Cancer       Date:  2014-11-29       Impact factor: 5.705

Review 6.  [Consent management and workflows for cross-sectoral patient records and teleconsultations].

Authors:  J Bauer; S Rohner-Rojas; M Holderried
Journal:  Radiologe       Date:  2020-05       Impact factor: 0.635

7.  The role of the general practitioner in cancer care: a survey of the patients' perspective.

Authors:  V Lang; S Walter; J Fessler; M J Koester; D Ruetters; J Huebner
Journal:  J Cancer Res Clin Oncol       Date:  2017-02-10       Impact factor: 4.553

8.  Characteristics and external validity of the German Health Risk Institute (HRI) Database.

Authors:  Frank Andersohn; Jochen Walker
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-11-03       Impact factor: 2.890

9.  Improving cooperation between general practitioners and dermatologists via telemedicine: study protocol of the cluster-randomized controlled TeleDerm study.

Authors:  Roland Koch; Andreas Polanc; Hannah Haumann; Gudula Kirtschig; Peter Martus; Christian Thies; Leonie Sundmacher; Carmen Gaa; Leonard Witkamp; Stefanie Joos
Journal:  Trials       Date:  2018-10-24       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.